Research programme: Hsp90 complex inhibitors - CGI PharmaceuticalsAlternative Names: CGI 242; Hsp90 complex inhibitors research programme - CGI Pharmaceuticals
Latest Information Update: 25 Jul 2007
At a glance
- Originator CGI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jul 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 10 Aug 2005 Cellular Genomics is now called CGI Pharmaceuticals
- 28 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)